Myelodysplastic Syndromes

← Back to Index(🩸 Hematology and Oncology)

Definition And Epidemiology

Clonal hematopoietic stem cell disorders.
Characterized by varying degrees of cytopenias secondary to ineffective and dysplastic hematopoiesis.
Increased propensity to evolve into acute myeloid leukemia (AML).
Pediatric incidence: 1.8 per million children per year (age 0-14 years).
Constitutes 4% of all pediatric hematological malignancies.
Distinguishing feature: Majority pediatric cases present with hypocellular bone marrow, contrasting adult hypercellular presentation. Mimics acquired and inherited bone marrow failure syndromes (IBMFS).

Pathophysiology

Disease initiates with apoptosis dominating, causing characteristic ineffective hematopoiesis.
Progressive accumulation of genetic abnormalities occurs over time.
Results in maturation arrest, enhanced cellular proliferation, and eventual transformation to AML.
Inherited predispositions (germline mutations) increasingly recognized as disease-initiating events in pediatric subsets. Secondary acquired somatic mutations drive disease progression.

Etiology And Predisposing Conditions

Categorized into primary (de novo) and secondary causes.

Category	Associated Conditions / Characteristics
Inherited Conditions	Fanconi anemia, Shwachman Diamond syndrome, Severe congenital neutropenia.
	Dyskeratosis congenita, telomere biology disorders, Diamond Blackfan anemia.
	GATA2 haploinsufficiency (MonoMac, Emberger syndrome, familial MDS/AML).
	SAMD9/SAMD9L mutations.
	Familial nonsyndromic MDS (mutations in ETV6, RUNX1/AML1, ANKRD26, DDX41, CEBPA).
Acquired Conditions	Prior chemotherapy or radiation therapy.
	Acquired aplastic anemia.

Occurs secondary to alkylating agents, topoisomerase II inhibitors, and radiation.
Represents 5% of all childhood MDS; occurs in 13% of children treated for prior malignancies.
Alkylating Agents/Irradiation: Latency 5-10 years. Characterized by deletions, loss of whole chromosomes, complex cytogenetics.
Topoisomerase II Inhibitors: Latency 1-3 years. Characterized by balanced translocations, commonly involving 11q23 (KMT2A/MLL gene).
Clinical Nuances: Older age at presentation, lower white blood cell (WBC) counts, less hepatosplenomegaly compared to de novo cases. Higher frequency of trisomy 8; fewer classic AML translocations. Inferior remission rates and overall survival (OS) compared to de novo cases.

Diagnostic Criteria And Classification

Requires at least two specific criteria for diagnosis.

Minimal Diagnostic Criteria

Sustained unexplained cytopenia (neutropenia, thrombocytopenia, or anemia).
At least bilineage morphologic myelodysplasia.
Acquired clonal cytogenetic abnormality in hematopoietic cells.
Increased blasts (≥5%).

World Health Organization Classification

Adapted specific categories for pediatric cases, primarily introducing Refractory Cytopenia of Childhood (RCC).

Category	Diagnostic Features
Refractory Cytopenia of Childhood (RCC)	Most common pediatric subtype (>50%). Thrombocytopenia, anemia, and/or neutropenia. <2% circulating blasts; <5% medullary blasts. Unequivocal dysplasia in ≥2 lineages, or >10% cells of one lineage.
MDS with Excess Blasts-1 (MDS-EB-1)	Cytopenia(s); <1x10^9/L circulating monocytes. 2-4% circulating blasts; 5-9% medullary blasts. Dysplasia involving ≥1 lineage(s); no Auer rods.
MDS with Excess Blasts-2 (MDS-EB-2)	Cytopenia(s); <1x10^9/L circulating monocytes. 5-19% circulating blasts; 10-19% medullary blasts. Dysplasia involving ≥1 lineage(s); ± Auer rods.
MDS with Isolated del(5q)	Anemia; normal/increased platelets. <1% circulating blasts; <5% medullary blasts. Megakaryocytes with characteristic nuclear hypolobulation. Isolated del(5q) abnormality. Rare in children.

Clinical Features

One-third of patients asymptomatic; identified via incidental cytopenias.
Symptoms relate directly to underlying cytopenias: pallor, bruising, petechiae, recurrent infections.
Thrombocytopenia, neutropenia, macrocytosis prominent.
Elevated fetal hemoglobin (HbF) common.
Lymphadenopathy and hepatosplenomegaly uncommon; signify advanced disease stage.

Diagnostic Evaluation

Laboratory And Blood Findings

Anemia (macrocytic or normocytic), thrombocytopenia, neutropenia.
Blood smear review required for dysplastic morphology.
HbF quantitation.
Chromosomal breakage analysis (diepoxybutane/mitomycin C) mandatory to exclude Fanconi anemia.
Flow cytometry for paroxysmal nocturnal hemoglobinuria (PNH) to exclude GPI-linked protein deficiencies.

Bone Marrow Examination

Aspirate and trephine biopsy essential.
Immunohistochemistry for CD34 and CD61 mandatory (CD61 crucial for micromegakaryocyte detection).
Findings range from hypocellular (RCC) to hypercellular with dysplastic changes.
Iron stain required; ring sideroblasts rare in pediatrics (consider mitochondrial cytopathies if present).

Cytogenetics And Molecular Genetics

Cytogenetics: Normal karyotype in 61-67% of RCC patients. Monosomy 7 most common abnormality, followed by trisomy 8.
Molecular Genetics: Adult MDS somatic mutations (SF3B1, TET2, ASXL1, EZH2, DNMT3A) rarely present in pediatric MDS.
Pediatric molecular landscape dominated by germline predispositions (RUNX1, GATA2, SAMD9/SAMD9L, ETV6).

Differential Diagnosis

Must rigorously exclude non-MDS causes of dyspoiesis.

IBMFS (Fanconi anemia, Diamond Blackfan anemia, Shwachman Diamond syndrome).
Immunologic, rheumatologic, metabolic, and mitochondrial disorders (e.g., Pearson syndrome).
Nutritional deficiencies (B12, folate, copper).
Viral infections, drug/toxin exposures.

Refractory Cytopenia Of Childhood Vs Severe Aplastic Anemia

Distinguishing hypocellular RCC from Severe Aplastic Anemia (SAA) is challenging but critical.

Feature	Refractory Cytopenia of Childhood (RCC)	Severe Aplastic Anemia (SAA)
Erythroid Lineage	Patchy, left-shifted erythropoiesis with increased mitoses.	Lacking foci; left-shifted erythroid cells absent or single small focus (<10 cells).
Myeloid Lineage	Markedly decreased, left-shifted myelopoiesis.	Lacking/markedly decreased; very few small foci with maturation.
Megakaryocytes	Markedly decreased.	Lacking or very few present.
Dysplasia	Dysplastic changes present (micromegakaryocytes via CD61 stain).	No dysplastic changes; micromegakaryocytes absent.

Prognosis And Survival

Adverse indicators: Monosomy 7 and complex karyotypes (≥3 abnormalities) predict rapid progression to leukemia and poor outcomes.
Blast counts: Two- to three-lineage cytopenia coupled with >5% bone marrow blasts implies poor prognosis.
Adult IPSS scoring systems lack validation and applicability in pediatric cohorts.
Hypocellular RCC patients may experience prolonged stable disease (months to years).
HSCT Outcomes: 3-year overall survival varies heavily by stage: RCC (74%), RAEB/MDS-EB (68%), RAEB-T (18%).
Long-term Disease-Free Survival (8-year, unrelated donor): RCC 51%, RAEB 35%, RAEB-T 29%. Relapse rates: RCC 4%, RAEB 23%, RAEB-T 29%.

Management And Treatment Options

Hematopoietic Stem Cell Transplantation (HSCT): Represents the sole curative therapy for pediatric MDS. Chemotherapy alone uniformly ineffective.
Donor Selection: High-resolution HLA typing mandatory at diagnosis. Matched related donor (MRD) strongly preferred. Essential to perform early molecular testing to avoid using family donors harboring identical germline predispositions.
Pre-HSCT Cytoreduction: Controversial in advanced disease (MDS-EB). AML-like induction chemotherapy recommended by some institutions to reduce blast burden; others advocate proceeding directly to HSCT to minimize toxicity. Decision depends on blast kinetics, cytogenetics, and donor availability.
Biological Agents: Hypomethylating agents (azacitidine, decitabine) improve overall survival in adult high-risk MDS but lack extensive pediatric data. Used on a case-by-case basis or within clinical trials. Not curative; delayed response times noted.
Supportive Care: Blood product transfusions and antimicrobial prophylaxis utilized while awaiting definitive HSCT.